Azacitidine (5-Azacytidine)

Name: Azacitidine (5-Azacytidine)
Brand: Selleck Chemicals
SKU: S1782
Rating: 5 (23 reviews)

For research use only.

Catalog No.S1782 Synonyms: 5-AzaC,Ladakamycin

23 publications

Azacitidine (5-Azacytidine) Chemical Structure

Molecular Weight(MW): 244.2

Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.

Selleck's Azacitidine (5-Azacytidine) has been cited by 23 publications

Cancer Cell, 2018, 34(5):724-740.e4

PubMed: 30423294 ( click the link to review the publication )

Cell, 2017, S0092-8674(17)31382-X

PubMed: 29249359 ( click the link to review the publication )

Cancer Cell, 2017, 31(6):833-843

PubMed: 28552327 ( click the link to review the publication )

Neoplasia, 2020, 22(3):142-153

PubMed: 32062068 ( click the link to review the publication )

J Clin Invest, 2019, 10.1172/JCI128571

PubMed: 31437130 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Environ Toxicol, 2019, 10.1002/tox.22873

PubMed: 31724259 ( click the link to review the publication )

Commun Biol, 2019, 2:272

PubMed: 31372511 ( click the link to review the publication )

Blood, 2018, 131(14):1576-1586

PubMed: 29437595 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 30412053 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):62

PubMed: 29728108 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2091-2099

PubMed: 30045927 ( click the link to review the publication )

Int J Mol Sci, 2018, 20(1)

PubMed: 30577584 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(9):1243-1254

PubMed: 28522693 ( click the link to review the publication )

Leuk Res, 2017, 58:91-97

PubMed: 28505595 ( click the link to review the publication )

Leuk Res, 2017, 58:91-97

PubMed: 28505595 ( click the link to review the publication )

Leuk Res, 2017, 56:36-43

PubMed: 28171800 ( click the link to review the publication )

Oncotarget, 2016, 8(60):100975-100988

PubMed: 29254139 ( click the link to review the publication )

Sci Transl Med, 2015, 7(290):290ra89

PubMed: 26041706 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17698-712

PubMed: 25989842 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description

Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.

Targets

DNA methyltransferase ^[1]
(Cell-free assay)

In vitro

Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. ^[1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. ^[2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Raji	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGH4UnUxNjFvNUCg{txO	M4\jSFEzNTd{IHi=		NYXtO2ptcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	Mm[2NlYyOzN{NE[=
Jurkat	M2XBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\6cVAvOS13MDFOwG0>	MnrzNVIuPzJiaB?=		NFns[mRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NFO1fGEzPjF\|M{K0Oi=>
CA46	NUeyPVh3TnWwY4Tpc44hSXO\|YYm=	M4XROlIxyqEEtV2=	MoLMOFghcA>?		NEjrfmtqdmO{ZXHz[ZPDqFCWUFyxxsBuWk6DIHX4dJJme3Orb36=	MVmyOlE{OzJ2Nh?=
Raji	MWHGeY5kfGmxbjDBd5NigQ>?	M{LjdVE2yqEEtV2=	MkXPOFghcA>?		NWjCVphucW6lcnXhd4V{yqCSVGDMNeKhdVKQQTDlfJBz\XO\|aX;u	NV7jN4V{OjZzM{OyOFY>
Jurkat	NU\KZXBWTnWwY4Tpc44hSXO\|YYm=	NGji[2I{NjYEoNM1US=>	MljIOFghcA>?		NX\ZeXNpcW6lcnXhd4V{yqCSVGDMNeKhdVKQQTDlfJBz\XO\|aX;u	NG\HU\|YzPjF\|M{K0Oi=>
MDA-MB-231	MnXLSpVv[3Srb36gRZN{[Xl?	M1XtdFEwOi53L{Wg{txO	M2XYelQ5KGh?		MXXk[YNz\WG\|ZYOgeIhmKFCWUF6xNkBmgHC{ZYPzbY9vKGG2IITo[UBkd26lZYLueJJifGmxbjDv[kA2yqEQvF2gOFjDqGh?	NYLZZngyOjV6MUeyNlk>
MDA-MB-231	MV\GeY5kfGmxbjDBd5NigQ>?	NHHYXYUyNzJwNT:1JO69VQ>?	MlqxOFghcA>?		M3\pcYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIFWtZ4FlcGW{aX6gcXJPSSCjdDD0bIUh[2:wY3XycpRz[XSrb36gc4YhOi53wrFOwG1nd3JiNElCpIg>	MUOyOVgyPzJ{OR?=
MDA-MB-231	M1fC[GZ2dmO2aX;uJGF{e2G7	NHrK[FMyNzJwNT:1JO69VQ>?	NWjWS5BpOjRxNEigbC=>		M4HZUYlv\HWlZYOgJJNq\26rZnnjZY51KFCDUmCgZ4xm[X[jZ3WgZYZ1\XJiNEigbC=>	MUOyOVgyPzJ{OR?=
MCF-7	M3nhcWZ2dmO2aX;uJGF{e2G7	NU\weFE1OS9{LkWvOUDPxE1?	MX2yOE81QCCq		M4jCPIlv[3KnYYPld{BRSVKSIHPs[YF3[WenwrC=	NUXEOXF5OjV6MUeyNlk>
MDA-MB-231	M2rJW2Z2dmO2aX;uJGF{e2G7	Mn;MNU8zNjVxNTFOwG0>	M1P5T\|I1NzR6IHi=		MUPpcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gcYlTVkFvMUK0JIF1KHSqZTDjc45k\XKwdILheIlwdiCxZjC1JO69VQ>?	MlvaNlU5OTd{Mkm=
A498	NHjJPJJHfW6ldHnvckBCe3OjeR?=	M1jvdlExKML3TR?=	NFXxPJE4OiCq		NGHod5dqdmS3Y3XzJJRp\SCDRFHNWHMyQCCpZX7lJIV5eHKnc4Ppc44>	NGnZPWQzPTV4OUC4Oi=>
CaKI-2	NH24VJBHfW6ldHnvckBCe3OjeR?=	MY[xNEDDvU1?	M1L2SVczKGh?		NIjzTWtqdmS3Y3XzJJRp\SCDRFHNWHMyQCCpZX7lJIV5eHKnc4Ppc44>	NH\WdlEzPTV4OUC4Oi=>
Ketr-3	MWLGeY5kfGmxbjDBd5NigQ>?	MYOxNEDDvU1?	MUi3NkBp		MmHNbY5lfWOnczD0bIUhSUSDTWTTNVgh\2WwZTDlfJBz\XO\|aX;u	NGDVUGozPTV4OUC4Oi=>
A253	NG\udY1HfW6ldHnvckBCe3OjeR?=	NUfZZVEzOTBiwsXN	NYHS[IJqOC12IHS=		MWXpcoNz\WG\|ZYOgeIhmKG2UTlGg[ZhxemW\|c3nvckBt\X[nbDDv[kB1cGViTUPSxsBi\nSncjCyOEBp	MUWyOVQ5PTV\|Nh?=
A253	MnOzSpVv[3Srb36gRZN{[Xl?	MnfLNVAhyrWP	NFvzdpY4OiCq		MV3pcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZidHjlJG0{WiCrbjDic5RpKG2nbXLyZY5mKGGwZDDjfZRwe2:uaXOgdJJmeGG{YYTpc45{	MlrVNlU1QDV3M{[=
A253	NG[3em5HfW6ldHnvckBCe3OjeR?=	M4fETVExKML3TR?=	M3fodFAuPCCm		M2P5c5Jm\HWlZYOgeIhmKDVvbXX0bJlt[3m2b4PpcoUh[2:wdHXueC=>	NV3xTGlHOjV2OEW1N\|Y>
PC3	NYjmTXFtTnWwY4Tpc44hSXO\|YYm=	NHSxeYQxNjJizszNxsA>	MVu0JIQ>		Mkj3bY5kemWjc3XzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiSVfGRnA4NCCVRmLQNUBidmRiU1zDOmEyPSClb33ibY5m\CC5aYToJGdUUzF{Nh?=	MlLQNlU1Pzd\|NEC=
MCF7	NULGcHM1TnWwY4Tpc44hSXO\|YYm=	Mn;NNE4{KM7:TdMg	M4O1eFQh\A>?		NIi4coVqdmO{ZXHz[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDJS2ZDWDduIGPGVnAyKGGwZDDTUGM3STF3IHPvcYJqdmWmIIfpeIghT1ONMUK2	NYfGdZdFOjV2N{ezOFA>
PC3	NETnVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTWNE4zKM7:TdMg	MXW0JIQ>		MnrM[IVkemWjc3XzJJRp\SClZXzsJIdzd3e2aDD0c{AzOC5\|JTDjc41jcW6nZDD3bZRpKEeVS{GyOi=>	NE[1c3UzPTR5N{O0NC=>
MCF7	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrtdJkxNjNizszNxsA>	Mn3SOEBl		NH3lOnVl\WO{ZXHz[ZMhfGinIHPlcIwh\3Kxd4ToJFI1NjhnIHPvcYJqdmWmIIfpeIghT1ONMUK2	M3fiZVI2PDd5M{Sw
BGC-823	MnfaSpVv[3Srb36gRZN{[Xl?	MXG1xsDPxE1?	NXzu[WVYPzJiaB?=		Mo\6[IVkemWjc3XzJJRp\SCSUlytN{Bxem:2ZXnuJIxmfmWuIIPp[45q\mOjboTsfS=>	MXqyOVQ4PTd\|Mx?=
MKN28	MUjGeY5kfGmxbjDBd5NigQ>?	M4P5dFXDqM7:TR?=	NIHQfWE4OiCq		NFfnblJl\WO{ZXHz[ZMhfGinIGDSUE0{KHC{b4TlbY4hdGW4ZXygd4lodmmoY3HueIx6	M2H0VFI2PDd3N{Oz
SGC-7901	NYP4OINLTnWwY4Tpc44hSXO\|YYm=	NXzBS\|E5PcLizszN	M3K1WFczKGh?		MVrk[YNz\WG\|ZYOgeIhmKFCUTD2zJJBzd3SnaX6gcIV3\Wxic3nncoln[2GwdHz5	M1PkT\|I2PDd3N{Oz
MKN45	MnHTSpVv[3Srb36gRZN{[Xl?	M4DGflXDqM7:TR?=	M2G2NVczKGh?		NX\3[ZJq\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>?	M{W5XFI2PDd3N{Oz
BGC-823	NGrifnRHfW6ldHnvckBCe3OjeR?=	MWW1xsDPxE1?	MYm3NkBp		NUjrNpQ5\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gVHJNNTNic3nncolncWOjboTsfS=>	M{f3PFI2PDd3N{Oz
MKN28	Mnz2SpVv[3Srb36gRZN{[Xl?	NVLC[GpTPcLizszN	MkKzO\|IhcA>?		NV\KWFJr\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gVHJNNTNic3nncolncWOjboTsfS=>	M4XJcVI2PDd3N{Oz
SGC-7901	Mn3JSpVv[3Srb36gRZN{[Xl?	MUG1xsDPxE1?	M2rrTlczKGh?		NWTaZ4hl\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gVHJNNTNic3nncolncWOjboTsfS=>	MV2yOVQ4PTd\|Mx?=
MKN45	NFj2dGFHfW6ldHnvckBCe3OjeR?=	M4jTdlXDqM7:TR?=	MmGyO\|IhcA>?		MY\k[YNz\WG\|ZYOgeIhmKG2UTlGg[ZhxemW\|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7	M1LtVlI2PDd3N{Oz
HREC	NELWPFBHfW6ldHnvckBCe3OjeR?=	M4jjW\|UwOTEEoN88US=>	NEm2d3I1QCCq		Mke0bY5lfWOnczDQSWRHKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MnzwNlU{PTJ5NEe=
HRPE	M2X6VWZ2dmO2aX;uJGF{e2G7	MV61M\|ExyqEQvF2=	M2rXNFQ5KGh?		NXv5PXRPcW6mdXPld{BRTUSIIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M4DMdVI2OzV{N{S3
HREC	NHLC[IpHfW6ldHnvckBCe3OjeR?=	MV61M\|ExyqEQvF2=	NVfLOoJoPDhiaB?=		NVzIb2p4\G:5bj3y[Yd2dGG2ZYOgc4YhXkWJRjygTWNCVS1zIDjuc5QheHKxdHXpckBt\X[nbDDpckBJWlCHIHPlcIx{MSxiSVytNe6zKGSxc3Wt[IVx\W6mZX70cJk>	MnH6NlU{PTJ5NEe=
HRPE	M{O2RWZ2dmO2aX;uJGF{e2G7	MYC1M\|ExyqEQvF2=	MWO0PEBp		M1;MSYRwf25vcnXneYxifGW\|IH;mJHZGT0ZuIFnMMVHPuixiYX7kJG1OWDJiZH;z[U1l\XCnbnTlcpRtgQ>?	NFTybIozPTN3Mke0Oy=>
MSCs	MWTGeY5kfGmxbjDBd5NigQ>?	NIC5NHoyOCEQvF2=	MX:yOEBp		M1m1U5Bzd22xdHXzJJRp\SClb33tbZRu\W62IH;mJG1US3NidH:gcZlw[2G{ZHnhcEBlcW[oZYLlcpRq[XSrb36=	NXP3eWw{OjV\|NUGzPVU>
HL-60	M4\LTmZ2dmO2aX;uJGF{e2G7	NHHCWlA2KM7:TR?=	NXnRfFlCPzJiaB?=	MoXYSG1UVw>?	MWjzbYdvcW[rY3HueIx6KHWycnXneYxifGW\|IGrOSlM5OiCneIDy[ZN{cW:w	NUPNdY5kOjV\|MUmwOFk>
MV4-11	MVXGeY5kfGmxbjDBd5NigQ>?	NFnmfGQ2KM7:TR?=	NE\LboM4OiCq	Mlf2SG1UVw>?	M3G5ZZNq\26rZnnjZY51dHlidYDy[Yd2dGG2ZYOgXm5HOzh{IHX4dJJme3Orb36=	MWmyOVMyQTB2OR?=
A2780	Mme3SpVv[3Srb36gRZN{[Xl?	MWq1JOK2VcLi	MnfsO{Bl		MYLpcoNz\WG\|ZYOgSG5CKG2ndHj5cIF1cW:wIHzleoVt	M4XsS\|I2Ojl7Nkm0
CP70	M3L3eWZ2dmO2aX;uJGF{e2G7	NIP0ZYM2KML3TdMg	M1;VfVch\A>?		MmDvbY5kemWjc3XzJGRPSSCvZYTofYxifGmxbjDs[ZZmdA>?	MVqyOVI6QTZ7NB?=
A2780	NVv6OZdUTnWwY4Tpc44hSXO\|YYm=	M1LHTFUhyrWPwrC=	NGq2XXo4KGR?		MXX3[YFs\W6\|IITo[UBt\X[nbDDv[kBu\XSqeXzheIlwdg>?	NWPi[Wh7OjV{OUm2PVQ>
CP70	NXX5c5VQTnWwY4Tpc44hSXO\|YYm=	M1WxSFUhyrWPwrC=	NVy3cZRkPyCm		MVT3[YFs\W6\|IITo[UBt\X[nbDDv[kBu\XSqeXzheIlwdg>?	MnHqNlUzQTl4OUS=
OCM3	NHjS[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjRdosxNjVxMT:yJO69VQ>?	MVS3JIQ>	MXzEUXNQ	NXr1b3hpcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NHPne3AzPTF2Nkm4NS=>
92.1	M2LCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrjcpZ[OC53L{GvNkDPxE1?	MV63JIQ>	MoT0SG1UVw>?	NWLsRYw3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NFnZeIQzPTF2Nkm4NS=>
OCM1	NEHoV5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;ONE42NzFxMjFOwG0>	M4TGelch\A>?	M3nyNmROW09?	M1fm[YlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MWqyOVE1Pjl6MR?=
OMM1	NF\rU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjnWGoxNjVxMT:yJO69VQ>?	MnW2O{Bl	MmTFSG1UVw>?	MnXUbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MV:yOVE1Pjl6MR?=
Mel 285	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUmwMlUwOS9{IN88US=>	MnjaO{Bl	MUjEUXNQ	M1;HXolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MkTCNlUyPDZ7OEG=
Mel 290	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHtSYQxNjVxMT:yJO69VQ>?	M3XIdVch\A>?	M4m2RWROW09?	NIL4PJpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NW[1UI4{OjVzNE[5PFE>
OCM3	NIW3U5RHfW6ldHnvckBCe3OjeR?=	NGnIU5gxNjVxMTFOwG0>	NH7hR2U1QCCq	MoTlSG1UVw>?	M13aTIRm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl?	MXKyOVE1Pjl6MR?=
92.1	MV7GeY5kfGmxbjDBd5NigQ>?	MU[wMlUwOSEQvF2=	MnXLOFghcA>?	M3nGWWROW09?	NXzhVmpZ\GWlcnXhd4V{KGOub37v[4VvcWOrdImg[I9{\S2mZYDlcoRmdnSueR?=	NH;LemIzPTF2Nkm4NS=>
OCM1	M3K3[mZ2dmO2aX;uJGF{e2G7	MlTNNE42NzFizszN	NEnvPHA1QCCq	MljPSG1UVw>?	Ml7P[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>?	Mm\RNlUyPDZ7OEG=
OMM1	NHq1c2pHfW6ldHnvckBCe3OjeR?=	MlHWNE42NzFizszN	MYG0PEBp	M1;XPGROW09?	NW\IWGVs\GWlcnXhd4V{KGOub37v[4VvcWOrdImg[I9{\S2mZYDlcoRmdnSueR?=	NELTO2IzPTF2Nkm4NS=>
Mel 285	MluxSpVv[3Srb36gRZN{[Xl?	NEnJXWkxNjVxMTFOwG0>	NX3NeYt[PDhiaB?=	M3jmNGROW09?	MVnk[YNz\WG\|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6	M2ezbFI2OTR4OUix
Mel 290	MU\GeY5kfGmxbjDBd5NigQ>?	NG\4eZMxNjVxMTFOwG0>	M4\0TFQ5KGh?	MXTEUXNQ	M3K0Z4Rm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl?	M4DhZ\|I2OTR4OUix
OCM3	MVXGeY5kfGmxbjDBd5NigQ>?	Mny2NE42NzFizszN	M2HIVVQ5KGh?	MWTEUXNQ	MXXk[YNz\WG\|ZYOgbY53[XOrb36g[I9{\SCmZYDlcoRmdnSuedMg	NWfKOVY6OjVzNE[5PFE>
Mel 290	MnHaSpVv[3Srb36gRZN{[Xl?	NHLPXpcxNjVxMTFOwG0>	MUG0PEBp	MkSzSG1UVw>?	NUm4VIFs\GWlcnXhd4V{KGmwdnHzbY9vKGSxc3Wg[IVx\W6mZX70cJnDqA>?	M1\CUVI2OTR4OUix
OMM1	M4P3UWZ2dmO2aX;uJGF{e2G7	MV6wMlUwOSEQvF2=	NFy0Uow1QCCq	NGXLW4JFVVOR	NGLUbmZl\WO{ZXHz[ZMhcW64YYPpc44h\G:\|ZTDk[ZBmdmSnboTsfeKh	NXrKbox2OjVzNE[5PFE>
OCM1	M2CyTmNmdGxiVnnhZoltcXS7IFHzd4F6	MVOwMlUwOSEQvF2=	NFHUTVE2KGR?	NG\WOpRFVVOR	MWXk[YNz\WG\|ZYOgdoFlcWG2aX;uMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHliaX7obYJqfGmxbh?=	Mo\xNlUyPDZ7OEG=
92.1	MkjpR4VtdCCYaXHibYxqfHliQYPzZZk>	MUSwMlUwOSEQvF2=	NWT6WXpnPSCm	M3vGPWROW09?	M2LXb4Rm[3KnYYPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDpcohq[mm2aX;u	M2rSTlI2OTR4OUix
OCM1	M3rGWmZ2dmO2aX;uJGF{e2G7	M{O0bVAvPS9zIN88US=>	NV;YfIV1PDhiaB?=	NGnndVZFVVOR	NFfJSVFk[XW\|ZYOg[4xw[mGuIFTORUBpgXCxbXX0bJlt[XSrb36gZZQhVC1zIILldIVifCCub3Pp	NWX0emZ7OjVzNE[5PFE>
OCM3	MorISpVv[3Srb36gRZN{[Xl?	NHL0ZWcxNjVxMTFOwG0>	MkfHOFghcA>?	M2TabWROW09?	MoXoZ4F2e2W\|IHfsc4JidCCGTlGgbJlxd22ndHj5cIF1cW:wIHH0JGwuOSC{ZYDlZZQhdG:laR?=	NYLjNotUOjVzNE[5PFE>
92.1	MUPGeY5kfGmxbjDBd5NigQ>?	M2DPSVAvPS9zIN88US=>	M2jVTVQ5KGh?	Mli0SG1UVw>?	M13SRYNifXOnczDncI9j[WxiRF7BJIh6eG:vZYTofYxifGmxbjDheEBNNTFicnXw[YF1KGyxY3m=	NYfUT2REOjVzNE[5PFE>
IMR32	NG\h[IdHfW6ldHnvckBCe3OjeR?=	Ml;KN{DPxE1?	M1\kWFczKGh?	MmjlSG1UVw>?	MnzjbY5lfWOnc9MgdFE6NUmQS{TkxsBmgHC{ZYPzbY9vyqC\|aXfubYZq[2GwdHz5	NX3FfFg6OjVzMES4OVA>
IMR5-75	M2HidWZ2dmO2aX;uJGF{e2G7	M2HOZVMh\|ryP	NVjsWVhtPzJiaB?=	NYfoSFl5TE2VTx?=	Mmi3bY5lfWOnc9MgdFE6NUmQS{TkxsBmgHC{ZYPzbY9vyqC\|aXfubYZq[2GwdHz5	NFG0eYMzPTFyNEi1NC=>
Be(2)-C	MYDGeY5kfGmxbjDBd5NigQ>?	MnzwN{DPxE1?	M4\ZeVczKGh?	NWDpU\|RRTE2VTx?=	M4TvOolv\HWlZYRCpJAyQS2LTlu0[OKh\XiycnXzd4lwdsLic3nncolncWOjboTsfS=>	MWOyOVExPDh3MB?=
Bxpc-3	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFr2eVY2NzFyIN88US=>	NYLEfo0zOjRxNEivO\|IhcA>?		Mor2bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gc4YhSniyYz2zJINmdGy\|IHnuJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XK\|	MoH6NlUxPjF5M{G=
Bxpc-3	NUnLeXZVSXCxcITvd4l{KEG\|c3H5	NV3pdpp7PS9zMDFOwG0>	NHXLbXQzPC92OD:3NkBp		NHPMd3ZqdmS3Y3XzJIFxd3C2b4Ppd{BqdiC2aX3lMUBidmRiY3;uZ4VzdnS{YYTpc44hdWGwbnXydy=>	M4XIeFI2ODZzN{Ox
Bxpc-3	M17oSGZ2dmO2aX;uJGF{e2G7	NYfLdG9pPS9zMDFOwG0>	M131UFI1NzR6L{eyJIg>		NXnHT4dt\GWlcnXhd4V{KM7{LXPheIVvcW5iZYjwdoV{e2mxbjDh[pRmeiB{NDDo	M2PKSlI2ODZzN{Ox
Bxpc-3	MVPGeY5kfGmxbjDBd5NigQ>?	NVPzcJJPPS9zMDFOwG0>	M4LjRVI1NzR6L{eyJIg>		M3T6NYRm[3KnYYPld{BkgWOuaX7ENUBmgHC{ZYPzbY9vKGG2IITo[UBkd26lZYLueJJifGmxbjDv[kAyOCEQvF2=	M4HUfVI2ODZzN{Ox
Bxpc-3	MXfGeY5kfGmxbjDBd5NigQ>?	M3ro[\|UwOTBizszN	M4L0clI1NzR6L{eyJIg>		MoK1[I94di2{ZXf1cIF1\VNiYz3tfYMhdVKQQTDlfJBz\XO\|aX;uJIlvKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYLz	Ml\UNlUxPjF5M{G=
HL-60	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfVNU4xKM7:TR?=	M1r2ZlQ5KGh?		MlTGd4lodmmoaXPhcpRtgSCrbnjpZol1eyCKTD22NEBk\WyuIHfyc5d1cMLi	NGHNUHMzPTB3MUGxPS=>
HL-60	M1XWR2Z2dmO2aX;uJGF{e2G7	MonxNU4xKM7:TR?=	NEDmOoY1QCCq		MmrMbY5kemWjc3XzJJAzOVeDRkGvR2lROcLiYX7kJINie3Cjc3WtN{BmgHC{ZYPzbY9vyqB?	M2TPTVI2ODVzMUG5
HL-60	MX\GeY5kfGmxbjDBd5NigQ>?	M176Z\|EvOCEQvF2=	MYO0PEBp		NEfPW3ll\WO{ZXHz[ZMhSmOuLYjMJIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm=	MWCyOVA2OTFzOR?=
HuTu-80	NH\iR4ZHfW6ldHnvckBCe3OjeR?=	MlvjNU82NzFyIN88US=>	MWi0PE84OiCq		NUTEXnBncW6lcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKGi3bXHuJG5RSzGOMTDtVm5CKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MVyyOFkxPDB4Mh?=
Caco2	MUPGeY5kfGmxbjDBd5NigQ>?	NIXUVIUyOCEQvF2=	NFX4XFk1QCCq		NEn5O\|hqdmO{ZXHz[ZMhVlCFMVyxJIV5eHKnc4Ppc44>	NIXxfZozPDlyNEC2Ni=>
HepG2	NHzUWZhHfW6ldHnvckBCe3OjeR?=	MnPONE0zPSEQvF2=	NWTVRndIOjRiaB?=		NETWWGll\WO{ZXHz[ZMhe3WkdHnsbZNqdi:tZYjpckB1gXCnIEmgLHBEW0t7KTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6	NXPINVRvOjR6NUW2OFY>
HepG2	Mn3ZSpVv[3Srb36gRZN{[Xl?	M{jQe\|AuOjVizszN	MV6yOEBp		NVfVbIxZcW6lcnXhd4V{KGyxdzDk[Y5{cXS7IHzpdI9xem:2ZXnuJJJm[2WydH;yJEhNTEyUKTDn[Y5mKGW6cILld5Nqd28EoB?=	MoDYNlQ5PTV4NE[=
HepG2	MmruSpVv[3Srb36gRZN{[Xl?	M4rUU\|ExKM7:bdMg	MnLINE0zPCCq		MXPk[YNz\WG\|ZYRCpHBEW0t7wrDhcoTDqEiPR1PSxsBmgHC{ZYPzbY9vKGGwZDDpcoNz\WG\|ZYOgUGRNWiCneIDy[ZN{cW:wIHHmeIVzKDZiaB?=	M4PDOFI1QDV3NkS2
HepG2	NHXGNI1HfW6ldHnvckBCe3OjeR?=	MnTPNVAh\|ryv	M{O1TFI1KGh?		MonxdJJwdW:2ZYOgZ5l1d3OxbHnjJI5mfXS{YXygcIlxcWRiYXPjeY12dGG2aX;uJIlv\GWyZX7k[Y51dHlib3[g[Zhw\2Wwb4XzJIxqeG:ycn;0[Ylvew>?	MUCyOFg2PTZ2Nh?=
HepG2	NVnBbnhMTnWwY4Tpc44hSXO\|YYm=	MWSxNEDPxG1?	NV;mPFh3OjRiaB?=		M1nyN5Bz\X[nboTzJHNTTUKSIIDyc4Nme3Orbne=	MUKyOFg2PTZ2Nh?=
HC45	NXzKTG1wTnWwY4Tpc44hSXO\|YYm=	NVe3dmJHPcL3TdMg	Mn;FOEBl		MYXy[YR2[2W\|IITo[UBu\XSqeXzheIlwdiCuZY\lcJMhd2ZiV1nGNUwhWDF4LDDDXGNNOTRuIF7LXFLjiJN\|LDDDSGgyNCCOQV3BNUwh[W6mIFPUUm5DOQ>?	MUOyOFc3OjhyOR?=
CNDT2	NEThSHdHfW6ldHnvckBCe3OjeR?=	M1i2W\|XDvU4EoB?=	NG\KT2Q1KGR?		MYPy[YR2[2W\|IITo[UBu\XSqeXzheIlwdiCuZY\lcJMhd2ZiV1nGNUwhWDF4LDDDXGNNOTRuIF7LXFLjiJN\|LDDDSGgyNCCOQV3BNUwh[W6mIFPUUm5DOQ>?	M{TiNFI1PzZ{OEC5
CNDT2	NIntZYhHfW6ldHnvckBCe3OjeR?=	M3rk[lXDvU4EoB?=	Ml\COEBl		MYnpcoNz\WG\|ZYOg[4Vv\SCneIDy[ZN{cW:wIH;mxsBYUUZzLDDQNVYtKEOGSEGsxsBNSU2DMT\|CpIFv\MLiQ2TOUmIy	MVSyOFc3OjhyOR?=
T-cells	MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HGZVUwOjBizszN	MV2wMVQ5KGh?		NVXjR\|JPcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MonRNlQ4PTd{OEO=
CD3+ T-cells	NYK2blFzTnWwY4Tpc44hSXO\|YYm=	MYK1M\|IxKM7:TR?=	M2fGVFQ5KGh?		NHjnXXp2eHKnZ4XsZZRmeyCyMUWg[ZhxemW\|c3nvci=>	MYGyOFc2PzJ6Mx?=
CD4+ T-cells	M1zuZ2Z2dmO2aX;uJGF{e2G7	MVy1M\|IxKM7:TR?=	M4P2d\|Q5KGh?		MoLzeZBz\We3bHH0[ZMheDF3IHX4dJJme3Orb36=	NGTyVGMzPDd3N{K4Ny=>
CD8+ T-cells	M1H0SmZ2dmO2aX;uJGF{e2G7	NXLmdZN2PS9{MDFOwG0>	MoXDOFghcA>?		MmPjeZBz\We3bHH0[ZMheDF3IHX4dJJme3Orb36=	NVmxVFdwOjR5NUeyPFM>
CD3+ T-cells	NY\HVVlVTnWwY4Tpc44hSXO\|YYm=	NIOyN5c2NzJyIN88US=>	NHPC[3A1QCCq		NVzaOVRtfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiRl;YVFM>	NFv2SGszPDd3N{K4Ny=>
CD4+ T-cells	MnTRSpVv[3Srb36gRZN{[Xl?	M{SyeVUwOjBizszN	M2DJN\|Q5KGh?		M1ryV5VxemWpdXzheIV{KHSqZTDlfJBz\XO\|aX;uJI9nKE[RWGCz	M{TXOlI1PzV5Mkiz
CD4+ T-cells	MmfYSpVv[3Srb36gRZN{[Xl?	Mo[yOU8zOCEQvF2=	NWXy[GFDPDhiaB?=		MUXy[YR2[2W\|IGTCSXQyyqCvUl7BJIV5eHKnc4Ppc44>	NXfVW4VoOjR5NUeyPFM>
CD4+ T-cells	NE\wOnZHfW6ldHnvckBCe3OjeR?=	MYC1M\|IxKM7:TR?=	NXzQXIxXPDhiaB?=		NHzlV3J2eHKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\sLiUl;S{tN1yqB?	NHzsXIYzPDd3N{K4Ny=>
CD4+ T-cells	MU\GeY5kfGmxbjDBd5NigQ>?	MkWyOU8zOCEQvF2=	Mn7iOFghcA>?		MkT6bY5pcWKrdIOgcYVud3K7IGStZ4VtdHN?	M{X3UVI1PzV5Mkiz
CD8+ T-cells	NUXCVpdITnWwY4Tpc44hSXO\|YYm=	MoTEOU8zOCEQvF2=	NE\1e3Q1QCCq		MlrBbY5pcWKrdIOgcYVud3K7IGStZ4VtdHN?	MYKyOFc2PzJ6Mx?=
CD3+ T-cells	NF7h[2JHfW6ldHnvckBCe3OjeR?=	M{nlOlUh\|ryP	MnvmOFghcA>?		NYLzd\|BDemWmdXPld{Btd26pLYTldo0hdWWvb4L5JINmdGxicHjlco91gXCn	MkPTNlQ4PTd{OEO=
U937	NXLWcHEySXCxcITvd4l{KEG\|c3H5	NXHyOohROTBizszN	NWLXfYJbPzJiaB?=		NVzFU44ycW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?=	M3zJe\|I1PjhyOE[1
HL-60	MoLCRZBweHSxc3nzJGF{e2G7	NYHGclh[OTBizszN	M1;VN\|czKGh?		Mn7DbY5lfWOnczDhdI9xfG:\|aYOgd4lodmmoaXPhcpRtgQ>?	Moe2NlQ3QDB6NkW=
MCF7	MW\GeY5kfGmxbjDBd5NigQ>?	NVjNPY93PSEQvF2=	MlX6OFghcMLi		MYXkbZNxdGG7czDz[Yxm[3SrdnWgeI95cWOrdImgeI94[XKmIIP1d5BmdmSnZDDNR2YuPyClZXzsdy=>	MWmyOFY{OzN3MB?=
MCF7	MmK5SpVv[3Srb36gRZN{[Xl?	MmjsNVAh\|ryP	NEXVW5MzPCCqwrC=		NVnUfodrcW6mdXPld{B1cGViY3zlZZZi\2Vib3[gZ4F{eGG\|ZTC3JIFv\CCSQWLQxsA>	M1qzOlI1PjN\|M{Ww
MCF7	NEW5cHBHfW6ldHnvckBCe3OjeR?=	M3q1dlDjiJNyLkWg{txOyqB?	NGXXc3Y4KGR?		MYrpcohq[mm2czD0bIUh\3Kxd4ToJG1ETi15IIT1cY9ze3CqZYLld{BqdiC\|dYPw[Y5{cW:wIHP1cJR2emW\|wrC=	NVTZflZuOjR4M{OzOVA>
MCF7	NFr5[FRHfW6ldHnvckBCe3OjeR?=	NFv4bmkxNjVizszNxsA>	NWnPcmI6OTRiZB?=		MmXvdoVlfWOnczD0bIUhe2m8ZTDv[kBOS0ZvNzDjc4xwdmmnczDlcYJm\GSnZDDpckB{d2[2IHHnZZI>	NG\oXWwzPDZ\|M{O1NC=>
MCF7	NHz6cGlHfW6ldHnvckBCe3OjeR?=	MVOwMlA26oDVMkCg{txO	NH7QPXAyKGR?		Ml\wdoVlfWOnczD0bIUh[2yxbnHsJJN2en[rdnHsJI9nKE2FRj23JINmdGy\|IHnuJI1wdm:uYYnldkBkfWy2dYLldy=>	NIWzdmczPDZ\|M{O1NC=>
T47D	M1zmOmZ2dmO2aX;uJGF{e2G7	MofyNE42KM7:TR?=	NIHwXVE1KGR?		MWjpcohq[mm2czD0eY1wenOyaHXy[UBnd3KvYYTpc44>	NWjyVXVmOjR4M{OzOVA>
MCF7	M4\teWZ2dmO2aX;uJGF{e2G7	Moe0NE426oDVMUCg{txO	MmHTOFghcMLi		M2TIbYlvcGmkaYTzJJRp\SCpYYCgZ4xwe3W{ZTDpckB1cGVid3;1coQhcGWjbHnu[{Bie3OjeR?=	NYTTbnMyOjR4M{OzOVA>
MCF7	MnTqSpVv[3Srb36gRZN{[Xl?	NXrUepJkOC9zMDFOwG0>	NXrINJVQOjRiaB?=		NXj5[pZscW6qaXLpeJMhfGinIHHjeIl3cXS7IH;mJG1OWDl?	MV6yOFY{OzN3MB?=
MDA-MB-231	MoCwSpVv[3Srb36gRZN{[Xl?	NUK1dHhsOC534pETNVAh\|ryP	M1\WbVM3KGh?		NWP5UYIycW6qaXLpeJMhfGinIH3p[5JifGmxbh?=	MlfFNlQ3OzN\|NUC=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 ; PubMed: 28210112 Lung Cancer (Auckl) AZA and DAC cause DNMT1 depletion in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–5 µM) for 20 hours and DNMT1 protein was detected by Western blotting of cell extracts. Alpha-tubulin was used as a loading control. c-PARP / p-H2AX / H2AX; PubMed: 28210112 Lung Cancer (Auckl) AZA, but not DAC, induces markers of DNA damage and apoptosis in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–10 µM) for 48 hours and Western blotting of cell extracts was used to detect DNMT1, cleaved-PARP, phospho-histone-H2AX(䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘	28210112
Immunofluorescence	HMGB1 ; PubMed: 29097772 Sci Rep U2OS cells stably expressing a GFP-HMGB1 fusion were maintained in control conditions (Ctrl), suberoylanilide hydroxamic acid (SAHA), azacitidine (AZA) for 24 h or 48 h, followed by assessment of cytoplasmic GFP-HMGB1 fluorescence intensity (A,B) or endog䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕𢡄⟼෕䀷痗⟼෕౴⟼෕㵶痗⟼෕뺖᎒泌Itemｾ᎒	29097772
Growth inhibition assay	Cell viability ; PubMed: 28210112 Lung Cancer (Auckl) AZA and DAC differentially affect cell viability in a panel of NSCLC cell lines. Viability of A549, H460, and H1299 cells was assessed after 72 hours of treatment with AZA or DAC (0–25 µM). Error bars represent the standard error of mean of 3 independent 䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖	28210112

In vivo

Azacitidine inhibits polynucleotide synthesis in leukemic BDF₁ mice. ^[3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. ^[4]

Protocol

Cell Research:^[3]	- Collapse Cell lines: Leukemia L1210 cell Concentrations: 0.15 μg/mL Incubation Time: 3 days Method: 5 mL of L1210 cells (5 × 10³ cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter. (Only for Reference)
Animal Research:^[4]	- Collapse Animal Models: BDF1 mice bearing lymphoid leukemia L1210 Dosages: 3 mg/kg Administration: Daily i.p. injection (Only for Reference)

References

[4] Heby O, et al. Cancer Res. 1973, 33(1), 159-165.

- Collapse

Solubility (25°C)

In vitro	DMSO	48 mg/mL warmed (196.56 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Azacitidine (5-Azacytidine) SDF

Molecular Weight	244.2
Formula	C₈H₁₂N₄O₅
CAS No.	320-67-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	5-AzaC,Ladakamycin
Smiles	NC1=NC(=O)N(C=N1)C2OC(CO)C(O)C2O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04172844	Recruiting	Drug: Azacitidine\|Drug: Venetoclax\|Drug: Pevonedistat	Acute Myelogenous Leukemia	Ehab L Atallah\|Medical College of Wisconsin	January 13 2020	Phase 1
NCT04214860	Recruiting	Drug: APR-246\|Drug: Venetoclax\|Drug: Azacitidine	Myeloid Malignancy	Aprea Therapeutics	December 13 2019	Phase 1
NCT04128020	Recruiting	Drug: Nivolumab\|Drug: Azacitidine	Aml\|AML Adult	Sherif Farag\|Big Ten Cancer Research Consortium	October 10 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?
Answer:
S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

Choose Your Country or Region

By Signaling Pathways

By product type

Azacitidine (5-Azacytidine)